Gefitinib and pemetrexed purchases significantly reduced

On September 8, the office of the National Federation of Volume Purchasing suddenly issued a document that significantly lowered the procurement volume of two varieties of gefitinib and pemetrexed. Among them, gefitinib is the market hot varieties, and is also one of the two varieties with the most volume increase in this volume procurement, if three winning bids, the agreed procurement volume will be 12 times the 4+7 procurement volume. The surge in procurement volume makes this variety particularly attractive to the market. As of the publication of this article, the three qualified bidders are AstraZeneca, Qilu and Zhengda Tianqing, thus, this variety of competition has also become a spike duel between the original manufacturer and the local head enterprises. This makes the competition of this variety particularly attention-grabbing.

The company's market share has been reduced to 55% of the original purchase volume, which is a great benefit to those who lost their bids or those with less market share. 4+7, AstraZeneca won the BID with a 76% reduction, while Qilu lost the bid in disgrace. This time, if AstraZeneca is still a brave man to cut the price of the winning bid, then, state-owned enterprises will again lose, although you can three winning bids, but it is difficult to shake AstraZeneca leading advantage, for local enterprises, the reduction in the number of banding has become a positive, at least the remaining available to compete for the market has increased.

If it is Zhengda Tianqing or Qilu price reduction more, especially Zhengda Tianqing, in the 4 + 7 bidding, Entecavir to 0.62 yuan per tablet won the bid, a price reduction of more than 90%. As a latecomer to the competition in May this year, Zhengda Tianqing may again give the market a staggering price. If the state-owned enterprise wins the bid with the floor price, AstraZeneca, which occupies more than 90% of the market, will not lose too much of the market at once. However, for the industry, the question that must be considered is, when encountering a major price reduction of the original drug companies, how will domestic pharmaceutical companies build their competitive advantage and moat, especially in marketing compliance requirements, after losing the price advantage, how to grab the market? Gefitinib is an example. After the last round of significant price cuts, the price of 50mg*10 tablets is 547 yuan, compared to the price of less than 1 yuan per piece of Atorvastatin, resulvastatin, etc., the profit margin is still very substantial, for domestic pharmaceutical enterprises, if the amount of procurement won the bid, will become an important source of profit. But when the original research drug low price to seize the market, where is the competitive advantage of domestic enterprises? If there is no way to cope with the competition, they will lose this important market, where is the survival space of pharmaceutical enterprises? For Qilu, Zhengda Tianqing and all domestic pharmaceutical companies, this is a problem that must be considered.